跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
ADAKVEO crizanlizumab 10 mg/mL concentrate for solution for infusion vial - TGA Drug Approval Details
Approvals
/
TGA
/
ADAKVEO crizanlizumab 10 mg/mL concentrate for solution for infusion vial
Approved
STANDARD
ADAKVEO crizanlizumab 10 mg/mL concentrate for solution for infusion vial
Novartis Pharmaceuticals Australia Pty Ltd
🇦🇺 Therapeutic Goods Administration
Approval Date
May 30, 2025
Approval ID
eb8fc7f7110c2534
Company
Novartis Pharmaceuticals Australia Pty Ltd
Type
Standard
Approval Details
Approval Id
eb8fc7f7110c2534
Product Name
ADAKVEO crizanlizumab 10 mg/mL concentrate for solution for infusion vial
Artg Id
327317
Artg Name
ADAKVEO crizanlizumab 10 mg/mL concentrate for solution for infusion vial
Sponsor
Novartis Pharmaceuticals Australia Pty Ltd
Company Detail Path
/organization/novartis-pharmaceuticals-australia-pty-ltd
Artg Date
2021-04-08
Registration Type
Medicine
Therapeutic Good Type
Medicine
Licence Status
A
Licence Category
RE
Active Ingredients
Approved
Quick Info
Agency
TGA
Country
🇦🇺
Approval Date
May 30, 2025
Approval ID
eb8fc7f7110c2534
Type
Standard
Back to TGA Approvals
